KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018

  • ID: 4701809
  • Drug Pipelines
  • 32 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • BMS
  • Janssen
  • Merck
  • Pfizer
  • MORE
Summary

This KOL Insight briefing focuses on KOLs views of Pipeline Therapy Data Presented at EULAR 2018.

Questions topics -
  • Opinion on abatacept failing to achieve its primary endpoint in its Phase III LN trial
  • Views on the Phase III safety data for abatacept in LN
  • Expectations regarding abatacept’s future development in lupus
  • Opinion on ustekinumab’s ability to achieve partial improvements using SLEDAI-2K Responder Index-50
  • Views on ustekinumab’s Phase III trial design
  • Views on the absence of safety endpoints in the Phase III ustekinumab trial in SLE
  • Perception of etanercept’s efficacy in discoid lupus erythematosus
  • Opinion on etanercept’s safety data from the Phase II TARGET-DLE trial
Key Highlights
  • While most KOLs agreed that abatacept’s future in LN is uncertain, half of the KOLs highlighted that the drug has potential in lupus arthritis
  • Most KOLs highlighted that SLEDAI-2K Responder Index-50 data supports ustekinumab use in SLE
  • While most KOLs flagged that etanercept may exacerbate lupus features, half of the KOLs highlighted that etanercept has potential in lupus.
Scope
  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our Lupus key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based
  • Interviews performed during Aug 2018
KOL data is analyzed to produce -
  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts
Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on Pipeline Therapy Data Presented at EULAR 2018
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BMS
  • Janssen
  • Merck
  • Pfizer
  • MORE
  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications
  • Appendix
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Janssen
  • BMS
  • Pfizer
  • Merck
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4701809
Adroll
adroll